- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00085787
A Study of ARRY-142886 in Patients With Advanced Cancer
This is a Phase 1 study during which patients with advanced solid tumors will receive investigational study drug ARRY-142886.
This study has 2 parts. In the first part, patients will receive increasing doses of study drug in order to achieve the highest dose of study drug possible that will not cause unacceptable side effects. Approximately 25 patients from the US will be enrolled in Part 1 (Completed).
In the second part of the study, patients will receive the best dose of study drug, determined from the first part of the study, and will be followed to see what side effects the study drug causes and what effectiveness the study drug has, if any, in treating the cancer. Approximately 35 patients from the US will be enrolled in Part 2 (Completed).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80010
- University of Colorado Cancer Center, Anschutz Cancer Center
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic Rochester
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria (Part 2):
- Histopathologically or cytologically confirmed solid tumor that is refractory to standard therapies, or for which no standard therapies exist, or for which the Investigator feels no other active therapy is required for the duration of the study.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2.
- Estimated life expectancy of greater than or equal to 3 months.
- Patient must have a tumor that is accessible for biopsy and must consent to paired tumor biopsies and normal skin biopsies being taken pre- and post-dose of study drug.
- Additional criteria exist.
Key Exclusion Criteria (Part 2):
- Uncontrolled or symptomatic brain metastases.
- Use of investigational drug or device within 30 days prior to first dose of study drug.
- Major surgery within 30 days prior to study start.
- Radiotherapy or chemotherapy within 21 days prior to study start (not including palliative radiotherapy at focal sites).
- Pregnancy or lactation.
- Known positive serology for the human immunodeficiency virus (HIV), hepatitis B and/or hepatitis C.
- Additional criteria exist.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ARRY-142886
|
Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests, vital signs and electrocardiograms.
Time Frame: Part 1
|
Part 1
|
Establish the maximum tolerated dose (MTD) of study drug.
Time Frame: Part 1
|
Part 1
|
Assess the biological activity of the study drug in tumors in terms of inhibition of extracellular signal-regulated kinase (ERK) phosphorylation.
Time Frame: Part 2
|
Part 2
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Characterize the pharmacokinetics (PK) of the study drug in terms of plasma concentrations.
Time Frame: Part 1 and Part 2
|
Part 1 and Part 2
|
Characterize the pharmacodynamic (PD) activity of the study drug on biomarkers.
Time Frame: Part 1 and Part 2
|
Part 1 and Part 2
|
Assess the efficacy of the study drug in terms of tumor dimension assessment.
Time Frame: Part 1 and Part 2
|
Part 1 and Part 2
|
Confirm the safety of the study drug at the MTD as determined by adverse events, clinical laboratory tests, vital signs and electrocardiograms.
Time Frame: Part 2
|
Part 2
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ARRY-0401
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Cancer
-
STORM Therapeutics LTDRecruitingCancer | Advanced Solid Tumor | Advanced CancerUnited States
-
Merck Sharp & Dohme LLCCompletedAdvanced Cancer Relapsed | Advanced Cancer Refractory
-
Teon Therapeutics, Inc.Merck Sharp & Dohme LLCTerminatedCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
BiOneCure Therapeutics Inc.RecruitingCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Zhejiang UniversityRecruitingAdvanced Colorectal Cancer | Advanced Hepatocellular Carcinoma | Advanced Gastric Cancer | Advanced Pancreatic CancerChina
-
PfizerTerminatedAdvanced Solid Tumors | Advanced CancerUnited States
-
Avera McKennan Hospital & University Health CenterCompleted
-
AVEO Pharmaceuticals, Inc.CompletedAdvanced Cancer | Refractory CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
University Health Network, TorontoUniversity of UlmRecruiting
Clinical Trials on ARRY-142886, MEK inhibitor; oral
-
National Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | Recurrent Plasma Cell MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Adult Diffuse Large Cell LymphomaUnited States
-
National Cancer Institute (NCI)NRG OncologyCompletedRecurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedStage IV Skin Melanoma | Recurrent Melanoma | Stage III Skin MelanomaUnited States
-
Array Biopharma, now a wholly owned subsidiary...Completed
-
Array Biopharma, now a wholly owned subsidiary...CompletedRheumatoid ArthritisBrazil, Argentina, United States, Poland, Hungary, Peru, Romania
-
National Cancer Institute (NCI)Active, not recruitingLow Grade Glioma | Recurrent Visual Pathway Glioma | Refractory Visual Pathway Glioma | Recurrent Childhood Pilocytic Astrocytoma | Recurrent Neurofibromatosis Type 1 | Refractory Neurofibromatosis Type 1United States
-
National Cancer Institute (NCI)CompletedRecurrent Thyroid Gland Carcinoma | Stage I Thyroid Gland Papillary Carcinoma | Stage II Thyroid Gland Papillary Carcinoma | Stage III Thyroid Gland Papillary Carcinoma | Stage IV Thyroid Gland Papillary CarcinomaUnited States, Canada
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States